Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings per share estimates for shares of Teladoc Health in a report released on Wednesday, October 30th. Leerink Partnrs analyst M. Cherny now anticipates that the health services provider will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Teladoc Health's current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Teladoc Health's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.65) EPS.
Teladoc Health (NYSE:TDOC - Get Free Report) last issued its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.10. The company had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative return on equity of 9.40% and a negative net margin of 37.91%.
Several other equities analysts have also commented on the company. Stifel Nicolaus lowered their target price on Teladoc Health from $16.00 to $9.00 and set a "hold" rating for the company in a report on Thursday, August 1st. DA Davidson cut their price objective on shares of Teladoc Health from $12.00 to $8.00 and set a "neutral" rating on the stock in a research report on Thursday, August 1st. Barclays upped their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday. TD Cowen cut their price target on Teladoc Health from $9.00 to $8.00 and set a "hold" rating on the stock in a report on Thursday. Finally, Jefferies Financial Group increased their price objective on Teladoc Health from $8.00 to $10.00 and gave the stock a "hold" rating in a report on Tuesday, September 17th. Fourteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Teladoc Health has an average rating of "Hold" and a consensus price target of $11.97.
Check Out Our Latest Stock Analysis on TDOC
Teladoc Health Stock Performance
Shares of NYSE:TDOC traded down $0.34 on Monday, reaching $8.87. 9,941,938 shares of the company's stock were exchanged, compared to its average volume of 5,496,499. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The business's 50-day moving average is $8.48 and its two-hundred day moving average is $9.64. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -1.50 and a beta of 0.90.
Insider Transactions at Teladoc Health
In other Teladoc Health news, CMO Stephany Verstraete sold 15,000 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the completion of the sale, the chief marketing officer now directly owns 45,158 shares of the company's stock, valued at approximately $343,200.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Teladoc Health news, Director Thomas Mckinley purchased 7,000 shares of the stock in a transaction dated Tuesday, August 6th. The shares were acquired at an average price of $7.57 per share, for a total transaction of $52,990.00. Following the completion of the acquisition, the director now owns 31,077 shares of the company's stock, valued at $235,252.89. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the sale, the chief marketing officer now directly owns 45,158 shares of the company's stock, valued at approximately $343,200.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,051 shares of company stock valued at $257,565 over the last three months. Company insiders own 0.95% of the company's stock.
Hedge Funds Weigh In On Teladoc Health
A number of large investors have recently made changes to their positions in TDOC. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Teladoc Health by 2.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,588 shares of the health services provider's stock valued at $641,000 after buying an additional 1,352 shares during the period. Covestor Ltd raised its holdings in shares of Teladoc Health by 58.1% during the first quarter. Covestor Ltd now owns 3,817 shares of the health services provider's stock worth $57,000 after acquiring an additional 1,403 shares in the last quarter. Signaturefd LLC boosted its position in Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider's stock valued at $28,000 after purchasing an additional 1,715 shares during the last quarter. Swiss National Bank boosted its position in Teladoc Health by 0.6% during the first quarter. Swiss National Bank now owns 326,902 shares of the health services provider's stock valued at $4,936,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Teladoc Health by 84.5% in the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider's stock worth $40,000 after purchasing an additional 1,854 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company's stock.
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Featured Stories
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
